Paxman publishes newsletter on media attention and marketing during Breast Cancer Awareness Month
Today, Paxman publishes the October issue of its newsletter aimed at shareholders, investors and other interested parties.
This month’s issue highlights that Paxman was highlighted in several markets and also conducted a successful campaign in the United States during Breast Cancer Awareness Month in October. Entities and media highlighting Paxman Scalp cooling included Mayo Clinic Health System and the Good Morning America TV show in the USA, The Times of India, Brazilian TV and a national marketing campaign in Sweden in support of a breast cancer fund. Paxman’s #YouveGotThisCampaign was launched in the beginning of October and includes both digital and physical billboard advertising.
The newsletter also includes information on a survey by ASCO with 600 oncologists in the USA, which shows a significant positive attitude towards offering scalp cooling to most chemotherapy patients, international orders from Brazil, Hungary, France and Romania, and that Paxman has been successfully recertified by the Medical Device Single Audit Program.
To read the newsletter and subscribe for upcoming issues, follow this link:
Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug Administration (FDA) denied a request from the company to adjust the analysis of the pivotal AGENT study’s secondary endpoint of progression-free survival (PFS). Ho...
Isofol Medical AB (publ) når inte 300 PFS-händelser i AGENT-studien med nuvarande censureringsregler baserat på FDA-beslut
GÖTEBORG, Sverige, 3 december 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag att den amerikanska läkemedelsmyndigheten FDA avslagit en förfrågan från bolaget att få justera analysen av den pivotala AGENT-studiens sekundära effektmått 300 händelser av progressionsfri öv...
Rättelse: AroCell valberedning utsedd inför årsstämma 2022
Valberedningen, som är utsedd enligt de principer som antogs på årsstämman den 6 maj 2021 består av:• Clas Runnberg, representerar Labbex Förvaltnings AB• Jon Eiken, representerar eget aktieinnehav• Mikael Lönn, representerar eget aktieinnehavValberedningen ska före årsstämman 2022 utarbeta förslag...
Correction: AroCell nomination committee for the AGM 2022
The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 6, 2021, consists of: • Clas Runnberg, represents Labbex Förvaltnings AB• Jon Eiken, represents his own shares• Mikael Lönn, represents his own shares The nomination committee...